



Practical Insights in Novel Immune Therapies in Multiple Myeloma Educational Webinar

WEDNESDAY, MARCH 27, 2024 | VIRTUAL

6:00 - 6:05 PM EST	Welcome <i>Nikhil Munshi</i>
6:05 - 6:15PM EST	Overview of immune therapies and CAR T cells – defining the unmet need in relapsed refractory multiple myeloma; MOA of CAR T cells and TCEs and clinical data <i>Nikhil Munshi</i>
6:15 - 6:25 PM EST	Case study with discussion <i>Moderator: Nikhil Munshi</i> <i>Case Presenter: Shonali Midha</i>
6:25 - 6:35 PM EST	Patients and the process – defining patient selection for TCEs/CAR T cell therapy in practice - Understanding of CAR T eligibility to ensure the right patient is referred for CAR T therapy <i>Diana Cirstea</i>
6:35 - 6:45 PM EST	Case study with discussion <i>Moderator: Melissa Alsina</i> <i>Case Presenter: Omar Castañeda</i>
6:45 - 6:55 PM EST	Managing TCE/CAR T cell toxicities – practical tips for short and long-term adverse events associated with CAR T cell therapy (focus on needs for coordination between community centers and CAR T centers) <i>Ajai Chari</i>
6:55 - 7:05 PM EST	Case study with discussion <i>Moderator: Ajai Chari</i> <i>Case Presenter: Hamza Hassan</i>
7:05 - 7:15 PM EST	Managing relapse following novel immune therapies and future advances <i>Noopur Raje</i>
7:15 - 7:25 PM EST	Case study with discussion <i>Moderator: Noopur Raje</i> <i>Case Presenter: Diana Cirstea</i>
7:25 - 7:30 PM EST	Wrap up

The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:

This activity is supported by an independent grant from Bristol Myers Squibb

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC